Hereditary Breast and Ovarian Cancer Syndrome Clinical Trial
Official title:
Pilot Randomized Controlled Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
Verified date | November 2013 |
Source | Sheba Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ministry of Health |
Study type | Interventional |
Breast cancer (BC) is a major health problem and the most prevalent cancer among women.In a substantial proportion of familial cases, germ-line mutations in either BRCA1/2 can be detected. The only proven modality for active risk reduction (rather than passive early detection), is prophylactic surgery - prophylactic mastectomy and oophorectomy. While the majority of Jewish mutation carriers elect to undergo prophylactic oophorectomy at about age 40 years, in Israel only a minority perform prophylactic mastectomy. Another ramification of being a mutation carrier is the emotional stress associated with that discovery.Genetic information has profound implications for mutation carriers. The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named "The Work", enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life [ ]. Therefore, on the basis of previous data and beneficial observations we postulate that the clinical utility of IBSR mediation program may improve psychological and physical symptoms and quality of life among asymptomatic (oncologically healthy) BRCA1/ BRCA2 mutation carriers. Thus, we will conduct a pilot randomized controlled trial to scientifically investigate the effect of this intervention effects on BRCA1/2 mutation carriers.
Status | Completed |
Enrollment | 67 |
Est. completion date | June 2012 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 35 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Women who are carriers of one of the predominant Jewish mutations in BRCA1/2 genes, age 35 years or older, with no current or past history of cancer (except BCC), who are willing to sign an informed consent, and present mental clarity by the ability to comprehend and fulfill all the questionnaires. Exclusion Criteria: - Diagnosed with breast or ovarian cancer or any other cancer, self reported Pregnancy, risk reduction mastectomy, severe psychiatric diagnosis (e.g. bipolar disorder). |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Israel | Sheba Medical Center | Tel-aviv |
Lead Sponsor | Collaborator |
---|---|
Sheba Medical Center |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | global psychology functioning(GSI) | 12 Weeks | No | |
Primary | Sleep quality (PSQI) | 12 weeks | No | |
Secondary | Family support PSS-Fa | 12 weeks | No | |
Secondary | cancer related worry (CRW) | 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00535119 -
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
|
Phase 1 | |
Recruiting |
NCT03294343 -
Risk-Reducing Surgeries for Hereditary Ovarian Cancer
|
N/A | |
Completed |
NCT02956681 -
Statewide Communication to Reach Diverse Low Income Women
|
N/A | |
Completed |
NCT00305695 -
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
|
Phase 2 | |
Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
Active, not recruiting |
NCT02760849 -
Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
|
N/A | |
Recruiting |
NCT02653105 -
Women at Risk of Breast Cancer and OLFM4
|
N/A | |
Completed |
NCT02562170 -
Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study
|
Phase 4 | |
Recruiting |
NCT03162276 -
Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
|
Phase 3 | |
Not yet recruiting |
NCT01445275 -
Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
|
N/A | |
Recruiting |
NCT03015376 -
Inherited Susceptible Genes Among Epithelial Ovarian Cancer
|
||
Enrolling by invitation |
NCT04197856 -
Direct Information to At-risk Relatives
|
N/A | |
Completed |
NCT03784859 -
Tissue Expansion in Breast Reconstruction Without Drains
|
||
Completed |
NCT04544501 -
Enhance the Use of Genetic Counseling and Testing in Latinas
|
N/A | |
Completed |
NCT00609505 -
Telemedicine vs. Face-to-Face Cancer Genetic Counseling
|
N/A | |
Terminated |
NCT02705924 -
Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk
|
N/A | |
Completed |
NCT01333748 -
Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer
|
Phase 2 | |
Completed |
NCT00892736 -
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
|
Phase 1 | |
Recruiting |
NCT05677048 -
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
|
N/A |